Best-in-class
anticancer
drug
HLB develops the ‘Rivoceranib’, the Best-in-class
targeted therapy for unmet medical needs in cancer.
targeted therapy for unmet medical needs in cancer.
Leader of Global
Pharma
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
First-in-class drugs with continuous innovation and challenges.
IR Letter
-
About the Progress of the Global Ri...
∙ On February 26, HLB signed a binding term sheet with Adenchen Laboratories, the original developer of Rivoceranib, t... -
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th...
Press Release
-
HLB Group to put Covid-19 vaccine d...
South Korea’s HLB Group will acquire 40 billion won ($34.1 million) worth of third-party rights offerings and 50 billion... -
HLB’s Chinese partner to present ef...
HLB said its Chinese partner would showcase the efficacy of its anticancer drug candidate, rivoceranib, for various indi...